GlassScriptPhysician profile
Sadaf Taimur
NPI 1992871289
$8,665.82
in general payments reported to CMS, 2019-2025
77 companies · $2,718 in 2025
The $2,718 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,016 · 2020: $810 · 2021: $1,064 · 2022: $319 · 2023: $530 · 2024: $1,209 · 2025: $2,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,205 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,205.32 |
| Education | $251.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $824.83 | 2019-2025 | |
| Janssen Biotech, INC. | $711.07 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $501.94 | 2019-2025 | Calquence, Wainua |
| Pfizer INC. | $437.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $382.37 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genentech USA, INC. | $369.94 | 2019-2025 | Polivy, Venclexta, Tecentriq |
| Aveo Pharmaceuticals, INC. | $347.80 | 2022-2025 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $310.37 | 2019-2025 | Opdivo |
| Abbvie INC. | $278.83 | 2020-2025 | |
| Daiichi Sankyo INC. | $252.46 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Genzyme Corporation | $193.59 | 2019-2025 | |
| Lilly USA, LLC | $191.52 | 2019-2025 | Jaypirca, Kisunla, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $190.46 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $187.08 | 2019-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $178.07 | 2019-2023 | Imbruvica |
Show all 75 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadaf Taimur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.